Medivolve Announces Appointment of Peter Michel as New Chief Financial Officer
01 March 2022 - 9:00AM
Medivolve, Inc. (“
Medivolve” or the
“
Company”) (NEO: MEDV; OTC: COPRF; FRA:4NC)
announces the appointment of Peter Michel as the newly appointed
Chief Financial Officer of the Company effective immediately. Mr.
Michel will succeed Deborah Battiston.
Peter Michel is a CPA, CA and obtained a
Bachelor of Accounting and Financial Management from the University
of Waterloo. Mr. Michel formerly served in leadership roles in both
public and private companies with most recent focus in healthcare.
Additionally, he worked as a Senior Manager at BDO Canada LLP where
he worked in its audit and assurance practice. He has
expertise in strategic planning. financial reporting,
budgeting, acquisitions, cash management and audit.
Management and the board of directors of the
Company would like to thank Ms. Battiston for her services and
continued support of the Company.
About Medivolve, Inc.
Medivolve, Inc. (NEO: MEDV; OTC: COPRF;
FRA:4NC) is a healthcare technology company that seeks to reinvent
the U.S. healthcare system by leveraging a bespoke telehealth
platform, a clinical diagnostic network, and a data driven A.I.
framework to improve patient care.
The company was born out of the healthcare
crisis; to rethink, relearn and ultimately, reimagine a better way
for the healthcare system to operate. Our network of retail
collection sites plays an essential role in recovery by giving all
Americans access to fast, accurate, and inexpensive clinical
services when and where they need them. These centers will also
play a pivotal role in diagnostic testing, vaccinations, and other
point-of-care services. We are building disruptive technologies to
make it easier and faster to identify, treat, and prevent medical
issues. In doing so, we are working to give patients a holistic and
empowered view of their personal health.
Our long-term mission is to permanently fix
systemic issues in the nation's fragmented, overly complex, and
expensive healthcare system. Medivolve's next growth phase is about
pivoting the model and putting the pieces together to build a
profitable, SaaS-based health-tech company. We bring data-driven
clinical diagnostics, physician recommendations, and prescription
medications directly to people, all powered by a singular,
streamlined technology network. A powerful, singular purpose unites
our team: harnessing the transformative power of technology to
create healthier lives.
Underpinned by a bespoke, AI-driven platform,
we're developing a stealth system that constantly gets smarter,
takes the guesswork out of diagnostics, and flags critical health
issues immediately to deliver an unparalleled level of
personalization for each patient. We are determined to push the
boundaries of what's possible—not just for our business and our
shareholders, but for physicians and patients and the future of
healthcare. We strive to achieve a continuity of care never seen
before, a game-changer for our business and patients in the
communities we serve.
For investing inquiries, please
contact: David Preiner, info@medivolve.ca,
702-990-3737.
For U.S. media inquiries, please
contact: Kayla Slick, KaylaS@medivolve.net,
702-990-3737.
Cautionary Note Regarding
Forward-looking Information
This press release contains "forward-looking
information" within the meaning of applicable Canadian securities
legislation. Forward-looking information includes, but is not
limited to, statements with respect to the appointment and
resignation of officers and directors; the pursuit
by Medivolve of opportunities; and the merits or
potential returns of any such opportunities. Generally,
forward-looking information can be identified by the use of
forward-looking terminology such as "plans", "expects" or "does not
expect", "is expected", "budget", "scheduled", "estimates",
"forecasts", "intends", "anticipates" or "does not anticipate", or
"believes", or variations of such words and phrases or state that
certain actions, events or results "may", "could", "would", "might"
or "will be taken", "occur" or "be achieved". Forward-looking
information is subject to known and unknown risks, uncertainties
and other factors that may cause the actual results, level of
activity, performance or achievements of the Company, as the case
may be, to be materially different from those expressed or
implied by such forward-looking information. Although the Company
has attempted to identify important factors that could cause actual
results to differ materially from those contained in
forward-looking information, there may be other factors that cause
results not to be as anticipated, estimated or intended. There can
be no assurance that such information will prove to be accurate, as
actual results and future events could differ materially from those
anticipated in such statements. Accordingly, readers should not
place undue reliance on forward-looking information. The Company
does not undertake to update any forward-looking information,
except in accordance with applicable securities
laws. NEITHER THE NEO EXCHANGE NOR ITS REGULATION
SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE
ADEQUACY OR ACCURACY OF THIS RELEASE.
Medivolve (NEO:MEDV)
Historical Stock Chart
From Oct 2024 to Nov 2024
Medivolve (NEO:MEDV)
Historical Stock Chart
From Nov 2023 to Nov 2024